155 related articles for article (PubMed ID: 12124319)
41. Does PC-SPEs interact with warfarin?
Davis NB; Nahlik L; Vogelzang NJ
J Urol; 2002 Apr; 167(4):1793. PubMed ID: 11912419
[No Abstract] [Full Text] [Related]
42. Disseminated intravascular coagulation and PC-SPES: a case report and literature review.
Lock M; Loblaw DA; Choo R; Imrie K
Can J Urol; 2001 Aug; 8(4):1326-9. PubMed ID: 11564276
[TBL] [Abstract][Full Text] [Related]
43. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
Calvo A; Xiao N; Kang J; Best CJ; Leiva I; Emmert-Buck MR; Jorcyk C; Green JE
Cancer Res; 2002 Sep; 62(18):5325-35. PubMed ID: 12235003
[TBL] [Abstract][Full Text] [Related]
44. Herbal supplement PC-Spes for prostate cancer.
de Lemos ML
Ann Pharmacother; 2002 May; 36(5):921-6. PubMed ID: 11978173
[TBL] [Abstract][Full Text] [Related]
45. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.
Wang Y; Shao C; Shi CH; Zhang L; Yue HH; Wang PF; Yang B; Zhang YT; Liu F; Qin WJ; Wang H; Shao GX
Asian J Androl; 2005 Dec; 7(4):375-80. PubMed ID: 16281084
[TBL] [Abstract][Full Text] [Related]
46. Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases.
Oh WK; George DJ; Kantoff PW
Cancer; 2002 Feb; 94(3):686-9. PubMed ID: 11857300
[TBL] [Abstract][Full Text] [Related]
47. Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells.
Eder IE; Haag P; Basik M; Mousses S; Bektic J; Bartsch G; Klocker H
Mol Carcinog; 2003 Aug; 37(4):181-91. PubMed ID: 12891627
[TBL] [Abstract][Full Text] [Related]
48. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
49. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
Tamura K; Furihata M; Tsunoda T; Ashida S; Takata R; Obara W; Yoshioka H; Daigo Y; Nasu Y; Kumon H; Konaka H; Namiki M; Tozawa K; Kohri K; Tanji N; Yokoyama M; Shimazui T; Akaza H; Mizutani Y; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
Cancer Res; 2007 Jun; 67(11):5117-25. PubMed ID: 17545589
[TBL] [Abstract][Full Text] [Related]
50. Androgen receptor-dependent and -independent mechanisms mediate Ganoderma lucidum activities in LNCaP prostate cancer cells.
Zaidman BZ; Wasser SP; Nevo E; Mahajna J
Int J Oncol; 2007 Oct; 31(4):959-67. PubMed ID: 17786330
[TBL] [Abstract][Full Text] [Related]
51. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.
D'Antonio JM; Ma C; Monzon FA; Pflug BR
Prostate; 2008 May; 68(7):698-714. PubMed ID: 18302219
[TBL] [Abstract][Full Text] [Related]
52. Equiguard suppresses androgen-dependent LNCaP prostate cancer cell proliferation by targeting cell cycle control via down regulation of the retinoblastoma protein Rb and induction of apoptosis via the release of cytochrome c.
Lu X; Hsieh TC; Wu JM
Int J Oncol; 2004 Dec; 25(6):1801-7. PubMed ID: 15547720
[TBL] [Abstract][Full Text] [Related]
53. Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients.
de la Taille A; Hayek OR; Buttyan R; Bagiella E; Burchardt M; Katz AE
BJU Int; 1999 Nov; 84(7):845-50. PubMed ID: 10532984
[TBL] [Abstract][Full Text] [Related]
54. Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2.
Tsui KH; Hsieh WC; Lin MH; Chang PL; Juang HH
Prostate; 2008 May; 68(6):610-9. PubMed ID: 18196550
[TBL] [Abstract][Full Text] [Related]
55. Induction of apoptosis and down-regulation of bcl-6 in mutu I cells treated with ethanolic extracts of the Chinese herbal supplement PC-SPES.
Hsieh TC; Ng C; Chang CC; Chen SS; Mittleman A; Wu JM
Int J Oncol; 1998 Dec; 13(6):1199-202. PubMed ID: 9824631
[TBL] [Abstract][Full Text] [Related]
56. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
[TBL] [Abstract][Full Text] [Related]
57. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
58. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates.
Ho SM
J Cell Biochem; 2004 Feb; 91(3):491-503. PubMed ID: 14755680
[TBL] [Abstract][Full Text] [Related]
59. Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer.
Tiwari RK; Geliebter J; Garikapaty VP; Yedavelli SP; Chen S; Mittelman A
Int J Oncol; 1999 Apr; 14(4):713-9. PubMed ID: 10087319
[TBL] [Abstract][Full Text] [Related]
60. Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15.
Huang CY; Beer TM; Higano CS; True LD; Vessella R; Lange PH; Garzotto M; Nelson PS
Clin Cancer Res; 2007 Oct; 13(19):5825-33. PubMed ID: 17908975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
